Inhibikase Therapeutics, Inc. Earnings Per Share (Basic)
Inhibikase Therapeutics, Inc. (IKT) reported Earnings Per Share (Basic) of -$0.11 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-11
- Inhibikase Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-06-30 was -$0.11.
- Inhibikase Therapeutics, Inc. earnings per share, basic for the quarter ending 2026-03-31 was -$0.10.
- Inhibikase Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-12-31 was -$0.10.
- Inhibikase Therapeutics, Inc. earnings per share, basic for the quarter ending 2025-09-30 was -$0.13.
- Inhibikase Therapeutics, Inc. earnings per share, basic for fiscal 2025 was -$0.49.
- Inhibikase Therapeutics, Inc. earnings per share, basic for fiscal 2024 was -$1.16.
- Inhibikase Therapeutics, Inc. earnings per share, basic for fiscal 2023 was -$3.16.
- Inhibikase Therapeutics, Inc. earnings per share, basic for fiscal 2022 was -$4.28.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 3 month as first filed | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 6 month as first filed | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 9 month as first filed | Earnings Per Share, Basic 12 month | Earnings Per Share, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$0.11 10-Q · filed 2026-08-11 | -$0.21 10-Q · filed 2026-08-11 | -$0.31 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.43 derived: net income ÷ weighted average shares · filed 2026-08-11 | ||||
| 2026-03-31 | -$0.10 10-Q · filed 2026-05-12 | -$0.20 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.32 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.43 derived: net income ÷ weighted average shares · filed 2026-08-11 | ||||
| 2025-12-31 | -$0.10 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$0.23 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$0.34 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.49 10-K · filed 2026-03-26 | ||||
| 2025-09-30 | -$0.13 10-Q · filed 2025-11-14 | -$0.24 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.40 10-Q · filed 2025-11-14 | -$0.56 derived: net income ÷ weighted average shares · filed 2026-08-11 | ||||
| 2025-06-30 | -$0.11 10-Q · filed 2026-08-11 | -$0.26 10-Q · filed 2026-08-11 | -$0.43 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.64 derived: net income ÷ weighted average shares · filed 2026-08-11 | ||||
| 2025-03-31 | -$0.15 10-Q · filed 2026-05-12 | -$0.32 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.56 derived: net income ÷ weighted average shares · filed 2026-08-11 | -$0.82 derived: net income ÷ weighted average shares · filed 2026-08-11 | ||||
| 2024-12-31 | -$0.17 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$0.44 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$0.78 derived: net income ÷ weighted average shares · filed 2026-04-30 | -$1.16 10-K · filed 2026-03-26 | ||||
| 2024-09-30 | -$0.65 10-Q · filed 2025-11-14 | -$1.31 derived: net income ÷ weighted average shares · filed 2025-11-14 | -$2.03 10-Q · filed 2025-11-14 | -$2.47 derived: net income ÷ weighted average shares · filed 2025-11-14 | ||||
| 2024-06-30 | -$0.66 10-Q · filed 2025-08-14 | -$1.38 10-Q · filed 2025-08-14 | -$1.81 derived: net income ÷ weighted average shares · filed 2025-11-14 | -$2.61 derived: net income ÷ weighted average shares · filed 2025-11-14 | ||||
| 2024-03-31 | -$0.73 10-Q · filed 2025-05-14 | -$1.16 derived: net income ÷ weighted average shares · filed 2025-11-14 | -$1.95 derived: net income ÷ weighted average shares · filed 2025-11-14 | -$2.97 derived: net income ÷ weighted average shares · filed 2025-11-14 | ||||
| 2023-12-31 | -$0.47 derived: net income ÷ weighted average shares · filed 2025-03-27 | -$1.23 derived: net income ÷ weighted average shares · filed 2025-03-27 | -$2.24 derived: net income ÷ weighted average shares · filed 2025-03-27 | -$3.16 10-K · filed 2025-03-27 | -$3.57 10-K · filed 2024-03-27 | |||
| 2023-09-30 | -$0.86 10-Q · filed 2023-11-14 | -$1.96 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$2.93 10-Q · filed 2023-11-14 | -$3.95 derived: net income ÷ weighted average shares · filed 2024-11-14 | ||||
| 2023-06-30 | -$1.11 10-Q · filed 2023-08-14 | -$2.09 10-Q · filed 2023-08-14 | -$3.11 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$4.17 derived: net income ÷ weighted average shares · filed 2024-11-14 | ||||
| 2023-03-31 | -$0.98 10-Q · filed 2024-05-15 | -$0.16 10-Q · filed 2023-05-15 | -$1.99 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$3.05 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$4.15 derived: net income ÷ weighted average shares · filed 2024-11-14 | |||
| 2022-12-31 | -$1.01 derived: net income ÷ weighted average shares · filed 2024-03-27 | -$2.08 derived: net income ÷ weighted average shares · filed 2024-03-27 | -$3.18 derived: net income ÷ weighted average shares · filed 2024-03-27 | -$4.28 10-K · filed 2024-03-27 | -$0.72 10-K · filed 2023-03-31 | |||
| 2022-09-30 | -$1.06 10-Q · filed 2023-11-14 | -$0.18 10-Q · filed 2022-11-14 | -$2.16 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$3.26 10-Q · filed 2023-11-14 | -$0.55 10-Q · filed 2022-11-14 | -$1.28 derived: net income ÷ weighted average shares · filed 2023-11-14 | ||
| 2022-06-30 | -$1.10 10-Q · filed 2023-08-14 | -$0.18 10-Q · filed 2022-08-12 | -$2.20 10-Q · filed 2023-08-14 | -$0.37 10-Q · filed 2022-08-12 | -$0.79 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$0.94 derived: net income ÷ weighted average shares · filed 2023-11-14 | ||
| 2022-03-31 | -$0.18 10-Q · filed 2023-05-15 | -$0.38 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$0.56 derived: net income ÷ weighted average shares · filed 2023-11-14 | -$0.76 derived: net income ÷ weighted average shares · filed 2023-11-14 | ||||
| 2021-12-31 | -$0.20 derived: net income ÷ weighted average shares · filed 2023-03-31 | -$0.38 derived: net income ÷ weighted average shares · filed 2023-03-31 | -$0.58 derived: net income ÷ weighted average shares · filed 2023-03-31 | -$0.81 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | -$0.18 10-Q · filed 2022-11-14 | -$0.38 derived: net income ÷ weighted average shares · filed 2022-11-14 | -$0.61 10-Q · filed 2022-11-14 | |||||
| 2021-06-30 | -$0.22 10-Q · filed 2022-08-12 | -$0.47 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |